The 2025 Jefferies Global Healthcare Conference was successfully held in London from November 17–20. As one of the world’s most influential healthcare investment events, this year’s conference brought together approximately 4,500 corporate executives, institutional investors, and industry leaders. Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius (2696.HK), was invited to deliver a keynote presentation, offering a comprehensive overview of the company’s global expansion, the commercial potential of its innovative pipeline, and its latest R&D breakthroughs—showcasing the international capabilities and growth momentum of a leading Chinese biopharmaceutical innovator.

During his presentation, Dr. Zhu reviewed the significant progress Henlius has made in advancing its global strategy. With multiple products approved in Europe and the United States, the company’s global business continues to grow rapidly. Henlius has steadily strengthened its “systematic global expansion” capabilities, supported by an integrated platform spanning R&D, manufacturing, and regulatory affairs. This foundation has enabled sustainable global development and accelerated the global rollout of the company’s innovative products.

Focusing on innovation-driven R&D, Dr. Zhu highlighted the latest progress and market potential of four core innovative assets: serplulimab (trade name in Europe: Hetronifly^®), the world’s first PD-1 inhibitor approved for the first-line treatment of ES-SCLC; HLX22, a novel-epitope HER2 antibody with a differentiated mechanism of action; HLX43, a potentially best-in-class PD-L1 ADC with broad anti-tumour potential; and HLX07, an anti-EGFR mAb. Clinical results from these programs have been continuously presented at major international scientific congresses, underscoring Henlius’ growing global influence in oncology therapeutics.

Serplulimab has been approved in the UK, Germany, Singapore, India, and other markets. Its U.S. bridging study (ASTRIDE) has completed full enrolment, laying a solid foundation for a future Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). HLX43 has received clinical trial approvals in countries including China, the U.S., and Australia, initiated first-patient dosing in both China and the U.S., and obtained FDA Orphan Drug Designation (ODD) for thymic epithelial tumours. HLX22 is being evaluated in a global Phase III head-to-head trial versus the standard first-line regimen (trastuzumab + chemotherapy ± pembrolizumab) for gastric cancer, with enrolment advancing steadily across countries and regions including China, Australia, the U.S., Korea, and Latin America. The program has also received ODD from both the FDA and the European Commission (EC), reinforcing its strong global development potential. Meanwhile, the combination of HLX07 and serplulimab has demonstrated promising clinical activity in EGFR-high squamous non-small cell lung cancer, opening new possibilities for precision lung cancer treatment.

During the conference, Henlius also shared a “pipeline panorama” outlining its diversified early-stage R&D strategy. The company is currently advancing more than 50 early-stage programs with global competitiveness across multiple technology platforms, including fusion proteins, ADCs, and small molecules. By continuously expanding its early-stage portfolio, Henlius is building a sustainable and internationally oriented innovation engine.

Henlius is accelerating its growth under a dual strategy of continuous innovation and global expansion. With strong commercial execution and a forward-looking pipeline, the company is steadily progressing toward its vision of becoming a “globally deployed, innovation-driven international biopharmaceutical enterprise.” Dr. Zhu concluded, “Henlius is actively embracing global opportunities and advancing innovation and commercialization in line with international standards. By engaging closely with the global capital market and industry peers, we aim to further demonstrate Henlius’ innovation-powered global competitiveness and, through greater openness and collaboration, bring more affordable treatment options to patients around the world.”